Evidence map›Paper›PMID 32790695›Full record

ArticlePloS one2020

Identification of peptides interfering with the LRRK2/PP1 interaction.

Chang Zhi Dong, Heriberto Bruzzoni-Giovanelli, Yanhua Yu, Karim Dorgham, Christophe Parizot, Jean Marc Zini, Jean Yves Brossas, Pierre Tuffery, Angelita Rebollo

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Isolation of Primary Hepatocytes for Testing Tumor Penetrating Peptides.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Chang Zhi DongUniversité de Paris, ITODYS, Paris, France.
Heriberto Bruzzoni-GiovanelliUniversité de Paris, Centre d'Investigation Clinique Inserm/AP-HP Hôpital Saint Louis, Paris, France.
Yanhua YuInstitute for Interdisciplinary Research, Jianghan University, Wuhan, China.
Karim DorghamSorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France.ORCID 0000-0001-9539-3203
Christophe ParizotSorbonne Université, Inserm, Centre d'immunologie et des Maladies Infectieuses-Paris (Cimi-Paris), Paris, France.
Jean Marc ZiniAP-HP Hopital Saint Louis, Paris, France.
Jean Yves BrossasSorbonne Université, Inserm, Centre d'immunologie et des Maladies Infectieuses-Paris (Cimi-Paris), Paris, France.
Pierre TufferyUniversité de Paris, BFA, Inserm, RPBS, Paris, France.
Angelita RebolloSorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France.ORCID 0000-0002-1293-9686
Inserm · FRAssistance Publique – Hôpitaux de Paris · FRJianghan University · CNUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Serine/threonine phosphatases are responsible for modulating the activities of the protein kinases implicated in the development of several pathologies. Here we identified by a PEP-scan approach a peptide of LRRK2, a Parkinson's disease associated protein, interacting with the phosphatase PP1. In order to study its biological activity, the peptide was fused via its N-terminal to an optimized cell penetrating peptide. We synthesized from the original peptide five interfering peptides and identified two (Mut3DPT-LRRK2-Short and Mut3DPT-LRRK2-Long) able to disrupt the LRRK2/PP1 interaction by competition in anti-LRRK2 immunoprecipitates. Using FITC-labelled peptides, we confirmed their internalization into cell lines as well as into primary cells obtained from healthy or ill human donors. We confirmed by ELISA test the association of Mut3DPT-LRRK2-Long peptide to purified PP1 protein. The peptides Mut3DPT-LRRK2-5 to 8 with either N or C-terminal deletions were not able to disrupt the association LRRK2/PP1 nor to associate with purified PP1 protein. The interfering sequences blocking the PP1/LRRK2 interaction were also fused to a shuttle peptide able to cross the blood brain barrier and showed that the newly generated peptides BBB-LRRK2-Short and BBB-LRRK2-Long were highly resistant to protease degradation. Furthermore, they blocked PP1/LRRK2 interaction and they penetrated into cells. Hence, these newly generated peptides can be employed as new tools in the investigation of the role of the LRRK2/PP1 interaction in normal and pathological conditions.

Indexed as

Binding SitesCell Line, TumorCells, CulturedHumansLeucine-Rich Repeat Serine-Threonine Protein Kinase-2OligopeptidesProtein BindingProtein Phosphatase 1ProteolysisLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, humanOligopeptidesProtein Phosphatase 1

Identifiers

PMID32790695
PMCPMC7425875
OpenAlexW3049450021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.